OncoLize (Maastricht-NL, 2017) is a carve-out from InGell Labs (Groningen-NL, 2010) and Branching Tree (Maastricht, 2008), all three founded by Mike de Leeuw with essential input from Leo de Leede.

Our company holds exclusive, worldwide licenses to the InGell depot-technology for oncology.

We have dedicated ourselves to develop products that deal with the urgent unmet needs for the ‘rare and deadly tumor diseases’.

Why?

  • Because we have seen to much suffering within our families, friends and colleagues.
  • Because little progress has been made for agressive Brain tumors, Pancreatic tumors and various other solid tumors.
  • Because most new developments for these diseases come out very expensive, marginally effective if at all, and certainly not accessible for all.

Over the past ten years we have shown the versatility and robustness of the InGell-technology.

We believe that everybody should have access to the best possible care for these aggressive tumor diseases.

We are certain that this can be done by localizing generic drugs and novel drugs alike, with much better effect, far less side-effects, and at much lower costs to the national healthcare systems.